Adam Burstain is an associate in Quinn Emanuel’s New York office. He joined the firm in 2024. His practice focuses on patent litigation, with a focus in life sciences and Hatch-Waxman litigation. Prior to joining the firm, Adam worked in Columbia Law School’s Science, Health and Information Clinic. While there, he assisted the Department of Justice in their patent infringement suit against the manufacturers of Truvada in order to increase access to PrEP medication. Before practicing law, Adam was a molecular biology lab researcher studying the genetic causes of schizophrenia. Adam is also a licensed patent agent.
- Columbia Law School
(J.D., honors, 2024)- Kent Scholar
- Tulane University
(B.S. & B.F.A., Cell and Molecular Biology & Musical Theatre, summa cum laude, 2019)- Phi Alpha Delta – Academic Chair
- Gerald S. Gussack Award
- The State Bar of New York
- Unites States Patent and Trademark Office
- State of New York – Notary Public
- Kragness et al., Age-Dependent Expression Pattern in the Mammalian Brain of a Novel, Small Peptide Encoded in the 22q11.2 DS Region, 28 Gene Expression Patterns 95 (2018)
- Adam Burstain, The Ungraceful Grace Period: Defining 35 U.S.C. 102(b)’s Grace Period Exceptions Post-Helsinn, 15 Cybaris 284 (2024)